Beta Bionics, Inc. (BBNX)
NASDAQ:BBNX
Want to see BBNX full AI Analyst Report?
BBNX Stock Chart & Stats
$12.98
--
Market closed
$12.98
--
Day’s Range― - ―
52-Week Range$8.80 - $32.71
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.09M
Market Cap
$474.58M
Enterprise Value$425.89M
Total Cash (Recent Filing)$199.52M
Total Debt (Recent Filing)$6.91M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 04, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding44,561,695
10 Day Avg. Volume1,276,911
30 Day Avg. Volume1,094,836
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)4.29
Price to Sales (P/S)12.32
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue3.86
Enterprise Value/Gross Profit6.76
Enterprise Value/Ebitda-6.14
Forecast
1Y Price Target
$20.00Price Target Upside54.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.97
Revenue Forecast (FY)$132.61M
Bulls Say, Bears Say
Bulls Say
Product DifferentiationAnalyst highlights that the iLet system's easy-to-use closed-loop algorithm and learning capability can drive physician and patient adoption and enable share gains against incumbent insulin pumps.
Product Pipeline ExpansionAnalyst points to a progressing pipeline, including a patch-pump form factor and a bihormonal program, as factors that could expand the addressable market and serve as future revenue catalysts when key development milestones are achieved.
Regulatory Resolution ConfidenceAnalyst notes the warning letter appears focused on safety-reporting systems rather than the device itself and that an experienced quality team plus a manageable remediation plan should allow continued product sales with limited impact on profitability.
Bears Say
Operating Expense And Margin PressureAnalyst notes planned sales-force expansion and costs for new product configurations will increase operating and capital expenditures relative to sales, pressuring margins unless revenue growth meaningfully outpaces those expenses.
Patient Adoption And New StartsAnalyst warns that flat new patient starts and clinician surveys showing minimal prescription share gains raise concern about weaker market uptake and potential stock volatility.
Remediation Costs And Cash BurnAnalyst highlights that addressing the FDA warning letter's deficiencies could increase remediation costs, raise cash burn, and attract greater competitor and regulator scrutiny, which may strain financial flexibility.
Beta Bionics, Inc. News
BBNX FAQ
What was Beta Bionics, Inc.’s price range in the past 12 months?
Beta Bionics, Inc. lowest stock price was $8.80 and its highest was $32.71 in the past 12 months.
What is Beta Bionics, Inc.’s market cap?
Beta Bionics, Inc.’s market cap is $474.58M.
When is Beta Bionics, Inc.’s upcoming earnings report date?
Beta Bionics, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 96 days.
How were Beta Bionics, Inc.’s earnings last quarter?
Beta Bionics, Inc. released its earnings results on Apr 21, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.503 by $0.013.
Is Beta Bionics, Inc. overvalued?
According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued.
Does Beta Bionics, Inc. pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
What is Beta Bionics, Inc.’s EPS estimate?
Beta Bionics, Inc.’s EPS estimate is -0.59.
How many shares outstanding does Beta Bionics, Inc. have?
Beta Bionics, Inc. has 44,561,695 shares outstanding.
What happened to Beta Bionics, Inc.’s price movement after its last earnings report?
Beta Bionics, Inc. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.503. Following the earnings report the stock price went down -0.57%.
Which hedge fund is a major shareholder of Beta Bionics, Inc.?
Currently, no hedge funds are holding shares in BBNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beta Bionics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (54.08% Upside)
$20.00 (54.08% Upside)
Blogger Sentiment
Bullish
BBNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 753.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $150.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.51%
12-Months-Change
Fundamentals
Return on Equity
-23.00%
Trailing 12-Months
Asset Growth
-9.94%
Trailing 12-Months
Company Description
Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
BBNX Company Deck
BBNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive commercial momentum: strong 57% YoY revenue growth, meaningful gross margin expansion (59.5% in Q1), accelerating pharmacy channel adoption, raised full-year guidance and clear pipeline progress (Mint timing reiterated and Phase IIa for bihormonal started). Offsetting risks include a seasonal sequential decline in new patient starts, materially higher operating expenses (S&M at ~75% of revenue), ongoing FDA warning letter remediation, one-time tailwinds to Q1 gross margin that may not repeat, and continued investment-driven cash burn (~$25M in Q1). On balance, the positive operating results, guidance raises, cash runway and product/pipeline execution outweigh the near-term challenges and investments.View all BBNX earnings summariesBBNX Stock 12 Month Forecast
Average Price Target
$20.00
▲(54.08% Upside)
Technical Analysis
Labcorp Holdings
―
Tandem Diabetes Care
―
Envista Holdings
―
Sana Biotechnology
―
Fortrea Holdings Inc.
―
Ownership Overview
2.69% Insiders
10.39% Mutual Funds
1.49% Other Institutional Investors
76.52% Public Companies and
Individual Investors